LY2795050|cas:1346133-08-1|西域试剂

LY2795050,98.68%

产品编号：Bellancom-15708| CAS NO：1346133-08-1| 分子式：C₂₃H₂₂ClN₃O₂| 分子量：407.89

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-15708	￥1550.00	杭州北京（现货）
Bellancom-15708	￥2325.00	杭州北京（现货）
Bellancom-15708	￥3534.00	杭州北京（现货）
Bellancom-15708	￥8370.00	杭州北京（现货）
Bellancom-15708	￥13020.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

LY2795050

产品介绍

LY2795050 是一种短效选择性 KOR 拮抗剂。LY2795050 与 KOR 具有较高的亲和力，其 K_i 值为 0.72 nM。LY2795050 可用于中枢神经系统功能障碍的研究。

生物活性

LY2795050 is a short-acting selective κ(kappa)-opioid receptor (KOR) antagonist. LY2795050 has high affinity for the KOR with K_i value of 0.72 nM. LY2795050 can be used for the research of central nervous system dysfunction.

体外研究

LY2795050 displays high affinity with a K_i value of 0.72 nM for the KOR and has antagonist activity with a K_b value of 0.63 nM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

LY2795050 (i.p., 0.032-0.1mg/kg, 30 min) prevents dose-dependent grooming deficits produced by U50,488 in male and female mice.
LY2795050 (i.p., 0.032-0.1mg/kg, 0-150 min) has sexual dimorphism in some behavioral effects.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J mice (gonadally intact, adult, male and female)
Dosage:	0.032-0.1 mg/kg
Administration:	i.p., 0.032-0.1mg/kg, 30 min
Result:	Could dose-dependently prevent the self-grooming deficits caused by U50,488 with a 30-min pre-treatment. Not effected in blocking the effects of U50,488 with smaller dose (0.032mg/kg) in either males or females. Decreased immobility in the FST in males at a dose of 0.1mg/kg, but not in females, up to a dose of 0.32mg/kg. Prevented and also reversed (at 0.32mg/kg) the locomotor-depressant effects of U50,488 (10mg/kg), in males and females.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J mice (gonadally intact, adult, male and female)
Dosage:	0.032-0.1 mg/kg
Administration:	i.p., 0.032-0.1mg/kg, 30 min
Result:	Could dose-dependently prevent the self-grooming deficits caused by U50,488 with a 30-min pre-treatment. Not effected in blocking the effects of U50,488 with smaller dose (0.032mg/kg) in either males or females. Decreased immobility in the FST in males at a dose of 0.1mg/kg, but not in females, up to a dose of 0.32mg/kg. Prevented and also reversed (at 0.32mg/kg) the locomotor-depressant effects of U50,488 (10mg/kg), in males and females.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (122.58 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.4516 mL	12.2582 mL	24.5164 mL
5 mM	0.4903 mL	2.4516 mL	4.9033 mL
10 mM	0.2452 mL	1.2258 mL	2.4516 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (6.13 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.13 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (6.13 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.13 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.13 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.13 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。